Recommendations for serogroup B meningococcal vaccine for persons 10 years and older

Published

Journal Article

© Copyright 2016 by the American Academy of Pediatrics. This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2-or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation). Persons at increased risk of meningococcal serogroup B disease include the following: (1) persons with persistent complement component diseases, including inherited or chronic deficiencies in C3, C5- C9, properdin, factor D, or factor H or persons receiving eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT), a monoclonal antibody that acts as a terminal complement inhibitor by binding C5 and inhibiting cleavage of C5 to C5A; (2) persons with anatomic or functional asplenia, including sickle cell disease; and (3) healthy persons at increased risk because of a serogroup B meningococcal disease outbreak. Both serogroup B meningococcal vaccines have been shown to be safe and immunogenic and are licensed by the US Food and Drug Administration for individuals between the ages of 10 and 25 years. On the basis of epidemiologic and antibody persistence data, the American Academy of Pediatrics agrees with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that either vaccine may be administered to healthy adolescents and young adults 16 through 23 years of age (preferred ages are 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (category B recommendation).

Full Text

Duke Authors

Cited Authors

  • Byington, CL; Maldonado, YA; Barnett, ED; Davies, HD; Edwards, KM; Lynfield, R; Munoz, FM; Nolt, DL; Nyquist, AC; Rathore, MH; Sawyer, MH; Steinbach, WJ; Tan, TQ; Zaoutis, TE; Bernstein, HH; Brady, MT; Jackson, MA; Kimberlin, DW; Long, SS; Meissner, HC; Campos-Outcalt, D; Cohn, AC; Farizo, KM; Fischer, M; Gellin, BG; Gorman, RL; Halasa, N; Robinson, JL; Deseda-Tous, J; Simon, GR; Starke, JR; Frantz, JM

Published Date

  • September 1, 2016

Published In

Volume / Issue

  • 138 / 3

Electronic International Standard Serial Number (EISSN)

  • 1098-4275

International Standard Serial Number (ISSN)

  • 0031-4005

Digital Object Identifier (DOI)

  • 10.1542/peds.2016-1890

Citation Source

  • Scopus